Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Debt (2016 - 2026)

Amphastar Pharmaceuticals has reported Non-Current Debt over the past 13 years, most recently at $608.7 million for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 1.18% year-over-year to $608.7 million; the TTM value through Dec 2025 reached $608.7 million, up 1.18%, while the annual FY2025 figure was $608.7 million, 1.18% up from the prior year.
  • Non-Current Debt for Q4 2025 was $608.7 million at Amphastar Pharmaceuticals, roughly flat from $608.6 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $638.2 million in Q3 2023 and troughed at $30.5 million in Q2 2021.
  • A 5-year average of $355.2 million and a median of $537.6 million in 2023 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: fell 11.19% in 2021 and later surged 762.31% in 2023.
  • Year by year, Non-Current Debt stood at $74.8 million in 2021, then dropped by 2.59% to $72.8 million in 2022, then skyrocketed by 709.43% to $589.6 million in 2023, then grew by 2.04% to $601.6 million in 2024, then grew by 1.18% to $608.7 million in 2025.
  • Business Quant data shows Non-Current Debt for AMPH at $608.7 million in Q4 2025, $608.6 million in Q3 2025, and $607.7 million in Q2 2025.